Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms

International Journal of Psychiatry in Clinical Practice

Volumn 13, Issue 1, 2009, Pages 21-24

  Yoshimura, Reiji ^a,b   Ueda, Nobuhisa ^a   Ikenouch Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Hori, Hikaru ^a   Kakihara, Shingo ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

9 hydroxyrisperidone; Adherence; Extrapyramidal symptoms; Risperidone; Schizophrenia

Indexed keywords

PALIPERIDONE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM;

EID: 60749100049     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500802331532     Document Type: Article

References (14)

1. Bersani G, Bressa GM, Marini S, Pozzi F. Combined serotonin 5-HT2 and dopamine D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preclinical study with risperidone (R 64766). Hum Psychopharmacol 1990;5:225-31.
2. Castelao JF, Ferreria L, Gelders YG, Heylen SL. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res 1989;2:411-5.
3. Gelders YG, Heylen SL, Vanden BG, Bussche G, Reyntjens AJ, Janssen PAJ. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 1990;23:205-11.
4. Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, et al. Prediction of risperidone treatment with respect to plasma concentrations of risperidone, catecholamone metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005;20:71-8.
5. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
6. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatr Neurosci 2000;25:161-6.
7. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine (D2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-20.
8. Keith S. Advances in psychotic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:996-1008.
9. Meco G, Bedini L, Bonifati V, Sonsinl U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr Ther 1989;46:876-83.
10. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method of determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated other psychotropic drugs. J Chromatogr B Biomed Sci Appl 1997;698:209-16.
11. Riedel M, Schwarz MJ, Strassnig M, Spellmann L, Muller-Arends A, Weber K, et al. Risperidone plasma levels, clinical response and side effects. Eur Arch Psychiatry Clin Neurosci 2005;255:261-8.
12. Yoshimura R, Nakamura J, Ueda N, Terao T. Effect of risperidone plasma 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9- hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol 2000;15:175-80.
13. Yoshimura R, Ueda N, Shinkai K, Nakamura J. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 2003;18:107-11.
14. Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, et al. An open study of risperidone liquid in the acute phase of schizophrenia. Hum Psychopharmacol 2005;20:243-8.